We then analyzed pharmacokinetic characteristics of these candidate drugs using ADMETlab2.0, which indicated that Palbociclib, the first CDK4/6 inhibitor for breast cancer treatment with efficient blood–brain barrier (BBB) penetration, held promise for potentially assisting in GBM treatment through the identified target genes (Figure 9D). Here, CDK4 is linked to glioblastoma.